



衛生防護中心
Centre for Health Protection

**Scientific Committee on Emerging and Zoonotic Diseases
and
Scientific Committee on Vaccine Preventable Diseases**

**Consensus Interim Recommendations on the Use of CoronaVac
vaccine in children and adolescents in Hong Kong
(As of 19 November 2021)**

Introduction

The Scientific Committee on Vaccine Preventable Diseases (SCVPD) and the Scientific Committee on Emerging and Zoonotic Diseases (SCEZD) under the Centre for Health Protection of the Department of Health (JSC), joined by the Chief Executive's expert advisory panel (EAP), discussed the interim recommendations related to the use of CoronaVac vaccine in children and adolescents.

Use of CoronaVac vaccine in children and adolescents

2. The JSC-EAP noted the Advisory Panel on COVID-19 Vaccines recommended to extend the eligibility of the CoronaVac vaccine to cover children and adolescents aged 3 to 17 years, and to provide the relevant information to the JSC-EAP for examination, in order to facilitate with determining the priority groups for receiving the relevant vaccine.

3. The JSC-EAP noted that phase I and II trials on the use of CoronaVac vaccine in children and adolescents aged 3 to 17 years showed that CoronaVac vaccine is immunogenic, safe and well-tolerated.



衛生防護中心乃衛生署
轄下執行疾病預防
及控制的專業架構

*The Centre for Health
Protection is a
professional arm the
Department of Health for
disease prevention
and control*

4. In addition, ongoing phase III trials on the use of CoronaVac vaccine in children and adolescents aged 3 to 17 years showed that CoronaVac vaccine was well-tolerated.
5. Available information from mass vaccination campaign in mainland China among children and adolescents 3 to 17 years old (with over 100 million doses of CoronaVac vaccine administered) has not shown major safety issues.
6. Given the local context and real world experience accrued outside Hong Kong, the JSC-EAP recommended the use of CoronaVac vaccine in children and adolescents 12 to 17 years of age for priority deployment, with a view of extending to children of a younger age group at a later stage.
7. For adolescents aged 12 to 17 years, the JSC-EAP recommended two doses of CoronaVac vaccine to be given 28 days apart.
8. This consensus interim recommendations document provides an update on top of the previous JSC-EAP interim recommendations dated 19 February 2021, 15 September 2021 and 27 October 2021.

November 2021

The copyright of this paper belongs to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. Contents of the paper may be freely quoted for educational, training and non-commercial uses provided that acknowledgement be made to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. No part of this paper may be used, modified or reproduced for purposes other than those stated above without prior permission obtained from the Centre.